Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Kaken Pharmaceutical Co's PB Ratio or its related term are showing as below:
TSE:4521'
s PB Ratio Range Over the Past 10 Years
Min: 0.85 Med: 1.23 Max: 3.2
Current: 1
During the past 13 years, Kaken Pharmaceutical Co's highest PB Ratio was 3.20. The lowest was 0.85. And the median was 1.23.
TSE:4521's PB Ratio is ranked better than 76.11% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs TSE:4521: 1.00
During the past 12 months, Kaken Pharmaceutical Co's average Book Value Per Share Growth Rate was -1.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Kaken Pharmaceutical Co was 15.90% per year. The lowest was 2.00% per year. And the median was 6.90% per year.
Back to Basics: PB Ratio
Kaken Pharmaceutical Co (TSE:4521) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kaken Pharmaceutical Co (TSE:4521) has a PB Ratio of 1.00 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kaken Pharmaceutical Co and its competitors. This is 19% below median its historical median of 1.23. Over the past decade, Kaken Pharmaceutical Co's PB Ratio has ranged from 0.85 to 3.20. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #220 out of 921 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is Kaken Pharmaceutical Co's PB Ratio too high?
Kaken Pharmaceutical Co's current PB Ratio of 1.00 is 19% below median its 10-year median of 1.23. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 3.20. The Drug Manufacturers industry median PB Ratio is 1.86. Kaken Pharmaceutical Co's value of 1.00 is 46.2% below this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #220 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #220 out of 921 companies for PB Ratio. This places Kaken Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.86. Kaken Pharmaceutical Co's value of 1.00 is 46.2% below this benchmark. Historically, Kaken Pharmaceutical Co's own PB Ratio has ranged from 0.85 to 3.20 over the past decade. While the company's 10-year median is 1.23 vs. the industry median of 1.86, Kaken Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current PB Ratio of 1.00 is 46.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kaken Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current PB Ratio is 1.00, which is 19% below median its own 10-year median of 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,775.44, compared to a current price of 円3,900.00 — trading 3.3% above its estimated fair value. The current PB Ratio is 1.00, which is 19% below median its 10-year median of 1.23 and 46.2% below the Drug Manufacturers industry median of 1.86. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current PB Ratio is 1.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,900.00 is trading 3.3% above its estimated GF Value™ of 円3,775.44.
GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4521:
PB Ratio: 1.00 (19% below median its 10-year median of 1.23)
GF Value™: 円3,775.44 vs. price of 円3,900.00 (3.3% above fair value)
Industry Position: 46.2% below the Drug Manufacturers median (#220 of 921)
No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for TSE:4521
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4521 has been successfully added to your 
